Tag - VTL

Developments

Vital Therapies completes enrollment in VTL-308 pivotal trial

Vital Therapies’ (NASDAQ:VTL) VTL-308 Phase 3 trial to evaluate its cell-based therapy, ELAD, in subjects with severe alcoholic hepatitis has reached its enrollment target of 150 subjects. Subjects in VTL-308 were...

March 22, 2018

Feature

Vital Therapies pivotal ELAD trial to read out at end of third quarter

By Len Zehrs Vital Therapies (NASDAQ:VTL) expects to report top line data from its ELAD pivotal study, known as VTL-308, in patients with severe alcoholic hepatitis (sAH), an acute form of liver failure, by the end of...

March 20, 2018

Tag - VTL

Vital Therapies completes enrollment in VTL-308 pivotal trial

Vital Therapies pivotal ELAD trial to read out at end of third quarter

General

More